<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-17_20-46-05</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>Final Assessment:
Heavily pretreated metastatic ovarian cancer with severe anemia and stoma, on purely palliative trajectory; histology, biology, performance status, and exact metastatic pattern remain undefined/need urgent clarification.

Core Treatment Strategy:
- Prioritize symptom-led palliative care, including pain, nutrition, stoma support, and psychosocial/end-of-life discussions; clarify patient goals.  
- Urgently evaluate and stabilize anemia (source, transfusion need, iron/B12/folate, hemolysis) before any further systemic therapy decisions [@20250624|14501112].  
- Arrange updated contrast-enhanced CT/MRI with comparison to 2025-04-09 CT to define metastatic burden and complications; imaging currently outdated/limited.  
- Retrieve and review original pathology plus archived tissue for full histology, FIGO staging, and extended biomarkers; arrange re-biopsy only if necessary.  

Change Triggers:
- If anemia and performance status improve and patient desires, reconsider low-intensity systemic options aligned strictly with palliative intent and toxicities.  
- If imaging shows limited, complication-driving lesions (e.g., obstruction, painful metastasis), consider focused local palliation (radiation/intervention) over systemic escalation.</pre>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>2019.3.26 因卵巢癌外院手术，术后二次热灌注，多西+顺铂，化疗六次，多西+卡铂，2019.8 结束治疗PRR2019.10 血CA125升高，110左右，2019.11 挽救化疗 多柔比星脂质体3次因疫情停止治疗2021.5 再次肿瘤复发，白紫+贝伐化疗 六次，贝伐维持 2022.062022.7 多柔比星单药治疗 5次2023.1 口服安罗+尼拉2024.9 因肠梗阻停药2024.9 手术，肠造瘘，再次化疗，多柔比星+奈达铂化疗 3次，后联合免疫治疗，一次，SD，换药2025.4.9 外院CT： 卵巢癌多发转移东院肿瘤标志物（2025.06.25）：CA19-9:23.40U/ml,CA125:651.00U/ml↑,CA15-3:156.00U/ml↑,AFP:1.04ng/ml,CEA:1.13ng/ml,HE4:1210.00pmol/L↑,ROMA:99.50%(绝经前)↑,ROMA.:98.26%(绝经后)↑。东院生化检测（2025.06.24）：TBIL:3.6umol/l,DBIL:1.7umol/l,IBIL:1.9umol/L,ALP:143.6U/L↑,ALT:8.6U/l,AST:18.0U/L,ASTM:6.9U/L,LDH:209U/L,GGT:35U/L,TP:70.5g/l,ALB:39.5g/l↓,GELO:31.0g/l,A/G:1.27,NEFA:0.30mmol/L,PA:172mg/L↓,GLDH:3.8U/L,UREA:11.22mmol/l↑,CRE:93umol/l↑,UA:362umol/l↑。东院XN9000（2025.06.24）：WBC:7.8*10^9/L,LYM:18.2%↓,MID:6.2%,GRAN:74.1%,EOS:1.20%,BASO:0.30%,LYM#:1.4*10^9/L,MID#:0.5*10^9/L,GRAN#:5.8*10^9/L,EOS#:0.09*10^9/L,BASO#:0.02*10^9/L,RBC:2.41*10^12/L↓,HGB:67g/l↓,HCT:22.3%↓,MCV:92.5fl,MCH:27.8pg,MCHC:300.0g/l↓,RDWCV:16.1%↑,RDWSD:56↑,PLT:198*10^9/L,MPV:8.4fl,PCT:0.17%,PDW:7%↓,NL:4.14。</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;6 cycles&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;多西+顺铂&quot;,&quot;多西+卡铂&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;1.04 ng/ml&quot;,&quot;CA125&quot;:&quot;651.00 U/ml&quot;,&quot;CA15-3&quot;:&quot;156.00 U/ml&quot;,&quot;CA19-9&quot;:&quot;23.40 U/ml&quot;,&quot;CEA&quot;:&quot;1.13 ng/ml&quot;,&quot;HE4&quot;:&quot;1210.00 pmol/L&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;ROMA&quot;:&quot;99.50% (premenopausal); 98.26% (postmenopausal)&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Ovarian cancer with multiple metastases (CT 2025-04-09)&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[],&quot;histology&quot;:&quot;Unknown&quot;,&quot;laterality&quot;:&quot;Unknown&quot;,&quot;primary&quot;:&quot;Ovarian cancer&quot;,&quot;site&quot;:&quot;Ovary&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Yes&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;6 cycles&quot;,&quot;end_date&quot;:&quot;2019-08&quot;,&quot;intent&quot;:&quot;Adjuvant&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;regimen&quot;:&quot;多西+顺铂; 多西+卡铂&quot;,&quot;start_date&quot;:&quot;2019-03-26&quot;},{&quot;cycles&quot;:&quot;3 cycles&quot;,&quot;end_date&quot;:&quot;Unknown&quot;,&quot;intent&quot;:&quot;Salvage&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;多柔比星脂质体&quot;,&quot;start_date&quot;:&quot;2019-11&quot;},{&quot;cycles&quot;:&quot;6 cycles&quot;,&quot;end_date&quot;:&quot;2022-06&quot;,&quot;intent&quot;:&quot;Salvage&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;白紫+贝伐&quot;,&quot;start_date&quot;:&quot;2021-05&quot;},{&quot;cycles&quot;:&quot;5 cycles&quot;,&quot;end_date&quot;:&quot;Unknown&quot;,&quot;intent&quot;:&quot;Salvage&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;多柔比星&quot;,&quot;start_date&quot;:&quot;2022-07&quot;},{&quot;cycles&quot;:&quot;Unknown&quot;,&quot;end_date&quot;:&quot;2024-09&quot;,&quot;intent&quot;:&quot;Salvage&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;口服安罗+尼拉&quot;,&quot;start_date&quot;:&quot;2023-01&quot;},{&quot;cycles&quot;:&quot;3 cycles&quot;,&quot;end_date&quot;:&quot;Unknown&quot;,&quot;intent&quot;:&quot;Palliative&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;多柔比星+奈达铂&quot;,&quot;start_date&quot;:&quot;2024-09&quot;},{&quot;cycles&quot;:&quot;1&quot;,&quot;end_date&quot;:&quot;Unknown&quot;,&quot;intent&quot;:&quot;Palliative&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;联合免疫治疗&quot;,&quot;start_date&quot;:&quot;Unknown&quot;}],&quot;MAINTENANCE&quot;:&quot;Yes&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;2022-06&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;贝伐维持&quot;],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;No&quot;,&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;end_date&quot;:&quot;2019-08&quot;,&quot;evidence&quot;:&quot;CA125 ~110 in 2019.10&quot;,&quot;evidence_type&quot;:&quot;Biochemical&quot;,&quot;first_relapse_date&quot;:&quot;2019-10&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;2019-03-26&quot;,&quot;status&quot;:&quot;Unknown&quot;},{&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;end_date&quot;:&quot;Unknown&quot;,&quot;evidence&quot;:&quot;CT 2025-04-09: ovarian cancer multiple metastases&quot;,&quot;evidence_type&quot;:&quot;Radiologic&quot;,&quot;first_relapse_date&quot;:&quot;2025-04-09&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;start_date&quot;:&quot;2024-09&quot;,&quot;status&quot;:&quot;Unknown&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Unknown&quot;,&quot;RELAPSE&quot;:&quot;Yes&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;2019-10&quot;,&quot;evidence&quot;:&quot;CA125 ~110 in 2019.10&quot;,&quot;type&quot;:&quot;Biochemical&quot;},&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2019-03-26&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Surgery at outside hospital; postoperative hyperthermic perfusion&quot;},&quot;VISIT_DATE&quot;:&quot;2025-06-27&quot;,&quot;first_relapse_date&quot;:&quot;2019-10&quot;,&quot;last_platinum_end_date&quot;:&quot;Unknown&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2019-10&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;≈110&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-25&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;651.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;HE4&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-25&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;1210.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;pmol/L&quot;},{&quot;analyte&quot;:&quot;CA15-3&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-25&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;156.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;CA19-9&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-25&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;23.40&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;AFP&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-25&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;1.04&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;},{&quot;analyte&quot;:&quot;CEA&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-25&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;1.13&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;},{&quot;analyte&quot;:&quot;ALP&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-24&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;143.6&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/L&quot;},{&quot;analyte&quot;:&quot;ALB&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-24&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;39.5&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;g/l&quot;},{&quot;analyte&quot;:&quot;Hb&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-24&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;67&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;g/l&quot;},{&quot;analyte&quot;:&quot;RBC&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-24&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;2.41&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;*10^12/L&quot;},{&quot;analyte&quot;:&quot;WBC&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-24&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;7.8&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;*10^9/L&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2019-03-26&quot;,&quot;description&quot;:&quot;Initial surgery at outside hospital&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2019-03-26&quot;,&quot;description&quot;:&quot;Start adjuvant chemotherapy&quot;,&quot;type&quot;:&quot;ChemoStart&quot;},{&quot;date&quot;:&quot;2019-10&quot;,&quot;description&quot;:&quot;Biochemical relapse with CA125 elevation&quot;,&quot;type&quot;:&quot;Relapse&quot;},{&quot;date&quot;:&quot;2025-04-09&quot;,&quot;description&quot;:&quot;CT showed multiple metastases&quot;,&quot;type&quot;:&quot;Imaging&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;Unknown&quot;,&quot;last_admin_date&quot;:&quot;Unknown&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;多西+顺铂&quot;,&quot;多西+卡铂&quot;,&quot;多柔比星脂质体&quot;,&quot;白紫+贝伐&quot;,&quot;多柔比星&quot;,&quot;口服安罗+尼拉&quot;,&quot;多柔比星+奈达铂&quot;,&quot;联合免疫治疗&quot;,&quot;贝伐维持&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;Ovary&quot;,&quot;Multiple metastases&quot;],&quot;date&quot;:&quot;2025-04-09&quot;,&quot;findings&quot;:[&quot;Ovarian cancer with multiple metastases&quot;],&quot;impression&quot;:&quot;Ovarian cancer with multiple metastases&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2019-03-26&quot;,&quot;description&quot;:&quot;Surgery at outside hospital; postoperative hyperthermic perfusion&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;&quot;,&quot;regimen_or_test&quot;:&quot;&quot;},{&quot;date&quot;:&quot;2019-08&quot;,&quot;description&quot;:&quot;Completed adjuvant chemotherapy; PR&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;PR&quot;,&quot;regimen_or_test&quot;:&quot;多西+卡铂&quot;},{&quot;date&quot;:&quot;2019-10&quot;,&quot;description&quot;:&quot;CA125 increased to ~110&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;≈110 U/ml&quot;,&quot;regimen_or_test&quot;:&quot;CA125&quot;},{&quot;date&quot;:&quot;2019-11&quot;,&quot;description&quot;:&quot;Salvage chemotherapy with 多柔比星脂质体, stopped due to pandemic&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;3 cycles, stopped&quot;,&quot;regimen_or_test&quot;:&quot;多柔比星脂质体&quot;},{&quot;date&quot;:&quot;2021-05&quot;,&quot;description&quot;:&quot;Tumor recurrence treated with 白紫+贝伐&quot;,&quot;event_type&quot;:&quot;Relapse&quot;,&quot;key_result&quot;:&quot;6 cycles; bevacizumab maintenance&quot;,&quot;regimen_or_test&quot;:&quot;白紫+贝伐&quot;},{&quot;date&quot;:&quot;2022-06&quot;,&quot;description&quot;:&quot;Bevacizumab maintenance until 2022.06&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;&quot;,&quot;regimen_or_test&quot;:&quot;贝伐维持&quot;},{&quot;date&quot;:&quot;2022-07&quot;,&quot;description&quot;:&quot;多柔比星 monotherapy&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;5 cycles&quot;,&quot;regimen_or_test&quot;:&quot;多柔比星&quot;},{&quot;date&quot;:&quot;2023-01&quot;,&quot;description&quot;:&quot;Oral therapy started&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;&quot;,&quot;regimen_or_test&quot;:&quot;口服安罗+尼拉&quot;},{&quot;date&quot;:&quot;2024-09&quot;,&quot;description&quot;:&quot;Surgery with intestinal stoma for bowel obstruction; stopped oral therapy&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;&quot;,&quot;regimen_or_test&quot;:&quot;intestinal stoma&quot;},{&quot;date&quot;:&quot;2024-09&quot;,&quot;description&quot;:&quot;Chemotherapy 多柔比星+奈达铂&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;3 cycles&quot;,&quot;regimen_or_test&quot;:&quot;多柔比星+奈达铂&quot;},{&quot;date&quot;:&quot;Unknown&quot;,&quot;description&quot;:&quot;联合免疫治疗 once, achieved SD&quot;,&quot;event_type&quot;:&quot;Immunotherapy&quot;,&quot;key_result&quot;:&quot;SD&quot;,&quot;regimen_or_test&quot;:&quot;联合免疫治疗&quot;},{&quot;date&quot;:&quot;2025-04-09&quot;,&quot;description&quot;:&quot;External CT showed ovarian cancer multiple metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;multiple metastases&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2025-06-24&quot;,&quot;description&quot;:&quot;Biochemistry and CBC abnormalities&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;ALP 143.6↑; ALB 39.5↓; HGB 67 g/l↓; RBC 2.41↓&quot;,&quot;regimen_or_test&quot;:&quot;Biochemistry/CBC&quot;},{&quot;date&quot;:&quot;2025-06-25&quot;,&quot;description&quot;:&quot;Tumor markers elevated&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 651.00↑; HE4 1210.00↑; CA15-3 156.00↑; CA19-9 23.40; ROMA 99.50%/98.26%&quot;,&quot;regimen_or_test&quot;:&quot;CA125/HE4/CA15-3/CA19-9/ROMA&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Expert Debate (Round × Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Given Hgb 67 g/L and unclear ECOG/symptoms, please avoid new cytotoxic/immunotherapy until anemia workup/optimization and performance status are documented; align any further systemic plan with clarified patient goals.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>We need a recent contrast-enhanced CT or MRI with clear description of metastatic distribution and complications, compared with prior imaging, before reconsidering systemic therapy.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>pathologist</td><td>Please help retrieve the original surgical/biopsy pathology including histologic subtype, grade, and FIGO stage, as these are currently undocumented.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>nuclear</td><td>PET/CT should only be proposed if you judge it likely to change management in this palliative, heavily pretreated context; otherwise, prioritize CT/MRI.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Before planning any further systemic therapy, we need urgent clarification of performance status, anemia workup/management plan, and retrieval of full pathology plus molecular profile (BRCA/HRD, MSI/TMB, PD‑L1, HER2).</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>radiologist</td><td>Please confirm whether a recent contrast-enhanced CT with comparison is available and describe metastatic pattern/complications; advise if any additional imaging would realistically change palliative management.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>pathologist</td><td>We need the original surgical/biopsy report with histologic subtype, grade, FIGO stage, and key IHC markers to contextualize systemic options.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>nuclear</td><td>Only if prior imaging is inadequate or discordant, could you advise whether PET/CT is likely to alter management in this palliative, heavily pretreated setting?</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>oncologist</td><td>Current imaging description is too limited for response or complication assessment; a recent contrast-enhanced CT with prior comparisons is critical.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>nuclear</td><td>Please clarify whether a prior PET/CT was ever performed and if a new PET/CT would change management in this palliative setting.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>oncologist</td><td>Full ovarian pathology (histologic subtype/grade, FIGO stage, IHC) and biomarker panel (BRCA/HRD, MSI/TMB, PD-L1, HER2) are absent; final diagnosis and targetable markers cannot be confirmed without retrieving or repeating tissue-based workup.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>oncologist</td><td>Given progressive markers and undefined current disease pattern, please clarify whether a PET/CT has ever been performed or is planned; without this, I cannot comment on whether PET would meaningfully change staging or recurrence assessment.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>radiologist</td><td>Before deciding on PET/CT in this palliative setting, an updated, fully reported contrast CT/MRI with explicit documentation of disease distribution and complications is critical to judge PET’s incremental value.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Given Hgb 67 g/L [@20250624|14501112], please prioritize urgent anemia workup and stabilization before any further cytotoxic or intensive systemic therapy decisions.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Please arrange a detailed, contrast-enhanced CT or MRI with formal report describing disease distribution, complications, and comparison to 2025-04-09 CT to guide palliative planning and assess need for PET/CT.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>pathologist</td><td>Full original surgical/biopsy pathology (histologic subtype/grade, FIGO stage, IHC) is missing; please retrieve or repeat tissue workup to establish definitive subtype and enable biomarker testing.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>nuclear</td><td>PET/CT should be considered only after updated contrast CT/MRI is reviewed and if results are likely to change systemic or local palliative management; please comment once that imaging is available.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Before any further systemic therapy, please prioritize urgent anemia stabilization (including transfusion plan and etiology workup) and document ECOG/performance and symptom burden today, as these are currently unknown but critical for treatment intensity decisions.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>We need an updated contrast-enhanced CT or MRI with explicit comparison to 2025-04-09, delineating current metastatic burden and complications (bowel, liver, bone, pleura, etc.) to guide palliative strategy; PET/CT can be deferred until after this review.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>pathologist</td><td>Please help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO, key IHC) and advise on feasibility of additional biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) from existing tissue or need for re-biopsy.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>nuclear</td><td>For now, please hold off on PET/CT recommendations; after updated CT/MRI we will ask you to comment only if PET is likely to change palliative systemic/local management.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Before any further systemic therapy decisions, please prioritize urgent evaluation and stabilization of the severe anemia (Hgb 67 g/L) and document ECOG and current symptom burden today, as these are critical to determine treatment intensity and feasibility.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Please arrange an updated contrast-enhanced CT or MRI with explicit comparison to the 2025-04-09 CT, detailing current metastatic burden and any complications (e.g., bowel, liver, bone, pleural) to guide palliative planning; PET/CT can be reconsidered only after this review.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>pathologist</td><td>Kindly help retrieve or reconstruct the original ovarian pathology (histology, grade, FIGO stage, key IHC) and advise on feasibility of extended biomarker testing (BRCA/HRD, MSI/TMB, PD-L1, HER2) on existing tissue or whether re-biopsy is required.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>nuclear</td><td>For now, please hold off on PET/CT; after we review the updated contrast CT/MRI, we will ask you to comment only if PET is likely to change palliative systemic or local management.</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Heavily pretreated metastatic ovarian cancer with rising markers and severe anemia; intent now palliative disease control and symptom relief.  \n- Hold further cytotoxic therapy until anemia evaluated/treated and overall performance status, organ function, and symptoms documented (needs ECOG, comorbidities).  \n- Clarify current disease distribution and complication risk with updated contrast CT/MRI and prior imaging for comparison (sites, burden, obstruction, effusions).  \n- Obtain pathology report and biomarker profile including histology subtype, BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2 before systemic strategy change.  \n- Early palliative care, pain/nutrition support, transfusion assessment, and stoma function review; align next steps with patient goals and QoL.&quot;,
  &quot;oncologist&quot;: &quot;- Heavily pretreated platinum-exposed ovarian cancer with multiple metastases; current line palliative, progression suspected given rising CA125/HE4 [@20250625|13601595].  \n\n- Profound anemia (Hgb 67 g/l) may limit further cytotoxic therapy until transfusion/hematology optimization [@20250624|14501112].  \n\n- Hepatic and renal biochemistry largely acceptable; ALP mildly elevated, albumin slightly low—monitor for metastatic or nutritional impact [@20250624|14000385].  \n\n- No germline/somatic mutation data (e.g., homologous recombination, MSI, actionable targets); comprehensive molecular profiling urgently needed.  \n\n- Missing data: performance status, pain/symptom burden, prior toxicities, detailed CT report (sites/burden), and prior immunotherapy response to guide next-line choice.&quot;,
  &quot;radiologist&quot;: &quot;- CT shows ovarian malignancy with multiple metastatic sites; exact organs, lesion sizes, and counts are not specified and need updating [@IMAGING_STUDIES|2025-04-09].  \n- Overall metastatic disease burden and pattern (peritoneal vs visceral vs nodal) are undefined; require detailed current cross-sectional imaging report [unknown/needs update].  \n- No documented trend versus prior imaging; need earlier and interval scans to assess progression, stability, or response [unknown/needs update].  \n- Presence or absence of complications (bowel obstruction, ascites, hydronephrosis, thromboembolism) is not described; require updated imaging assessment [unknown/needs update].  \n- PET/CT status is unknown; clarify if performed to better define metabolic disease extent and occult metastases [unknown/needs update].&quot;,
  &quot;pathologist&quot;: &quot;- No histology, IHC, or site of disease available; definitive diagnosis, grade, and subtype are currently impossible to determine.  \n\n- Markedly elevated CA125 and HE4 with high ROMA suggest ovarian/pelvic Müllerian malignancy but are not diagnostic alone. [@MOLECULAR|2025-06-27]  \n\n- Tumor biomarkers HER2, MSI, PD-L1, TMB listed as unknown; these require dedicated tissue testing and report. [@MOLECULAR|2025-06-27]  \n\n- No germline or somatic pathogenic variants reported; comprehensive germline and tumor NGS panels appear incomplete/negative. [@MOLECULAR|2025-06-27]  \n\n- Need: surgical pathology report (primary site, histologic type, grade, FIGO stage) and IHC panel to finalize pathologic diagnosis.&quot;,
  &quot;nuclear&quot;: &quot;- No PET/CT metabolic data available for review; current PET report or images are required for staging/recurrence assessment (needs update).  \n\n- Known context: ovarian cancer with multiple metastases on prior imaging, but without metabolic characterization or current disease distribution [@IMAGING_CONTEXT|2025-04-09].  \n\n- Cannot comment on FDG uptake pattern, target lesions, or metabolic tumor volume without a contemporaneous PET/CT report (needs update).  \n\n- PET could meaningfully refine staging by clarifying extra-pelvic nodal/visceral involvement and detecting small-volume distant disease, once performed.  \n\n- For recurrence suspicion, PET would help distinguish metabolically active tumor from post-treatment change if prior therapy history and PET are provided (needs update).&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- Stabilize anemia urgently (transfusion/workup) before any further cytotoxic or intensive systemic therapy decisions [@20250624|14501112].  \n- Document ECOG, comorbidities, symptom burden, nutrition, and stoma function to refine palliative intent and treatment intensity (currently unknown).  \n- Obtain updated contrast CT/MRI with comparison to 2025‑04‑09 CT to define disease pattern and complications (details currently unknown).  \n- Retrieve/complete full pathology and molecular profile (histology, FIGO, BRCA/HRD, MSI/TMB, PD‑L1, HER2) to reassess systemic options.  \n- After anemia optimization and restaging, reconsider systemic vs best supportive care in MDT, aligned with patient goals and QoL.&quot;,
    &quot;oncologist&quot;: &quot;- Urgently investigate and correct anemia (transfusion, iron/B12/folate, bleeding/hemolysis workup) before deciding on further systemic therapy [@20250624|14501112].  \n\n- Obtain updated contrast-enhanced CT/MRI with report comparing to 2025-04-09 CT to define metastatic pattern and complications [@20250624|14000385].  \n\n- Retrieve full original ovarian pathology (histologic subtype, grade, FIGO stage, IHC) and perform comprehensive biomarker profiling; currently unknown/needs update.  \n\n- Defer additional cytotoxic or intensive systemic therapy until anemia, ECOG status, comorbidities, symptom burden, and prior toxicities are documented; currently unknown.  \n\n- Engage palliative care for symptom control, nutritional support, and anemia management now; revisit systemic options after clinical, imaging, and molecular reassessment.&quot;,
    &quot;radiologist&quot;: &quot;- Arrange updated contrast-enhanced CT/MRI with formal report, detailing metastatic distribution, size, and complications, compared to 2025‑04‑09 CT [@IMAGING_STUDIES|2025-04-09].  \n- Reassess need for PET/CT only after updated cross-sectional imaging, focusing on whether results would alter palliative local/systemic decisions [unknown].  \n- Explicitly document presence/absence of bowel obstruction, hydronephrosis, ascites, pleural effusion, and thromboembolism on new imaging for symptom-guided care [unknown].  \n- Quantify measurable target lesions (longest diameter, organ, segment) to enable future objective radiologic response assessments if therapy resumes [unknown].  \n- Retrieve and archive all prior imaging to establish radiologic trend (progression vs stability) against new study for prognosis and planning [@IMAGING_TRENDS|2025-04-09].&quot;,
    &quot;pathologist&quot;: &quot;- Retrieve full ovarian surgical/biopsy pathology including histologic subtype, grade, FIGO stage, and IHC; currently unknown/needs update.  \n\n- Perform comprehensive biomarker testing on available tissue: BRCA1/2, HRD, MSI/TMB, PD‑L1, HER2, and other actionable alterations; currently unknown.  \n\n- Confirm that existing pathology matches an ovarian/Müllerian primary and exclude other primaries or mixed histology; details unknown/needs update.  \n\n- Ensure pathology material adequacy (blocks/slides) for any planned additional molecular or IHC studies; current tissue status unknown.  \n\n- Once reports are retrieved, summarize a unified pathologic diagnosis for MDT, explicitly documenting subtype, grade, and biomarker profile.&quot;,
    &quot;nuclear&quot;: &quot;- No PET/CT available; prior metabolic imaging history and any existing PET reports remain unknown/needs update.  \n\n- Updated contrast-enhanced CT/MRI with formal report and comparison to 2025-04-09 CT is prerequisite before considering PET/CT [@IMAGING_CONTEXT|2025-04-09].  \n\n- After CT/MRI, PET/CT should be reserved for scenarios where clarifying extent or complications would change palliative systemic or local interventions.  \n\n- In this palliative, heavily pretreated setting, routine PET for staging alone is not justified without a specific, management-altering question.  \n\n- Once new CT/MRI and clinical goals are defined, re-evaluate whether PET could help distinguish active disease from treatment change or complications.&quot;
  },
  &quot;Round 2&quot;: {
    &quot;chair&quot;: &quot;- Prioritize anemia stabilization and etiology workup (including transfusion as needed) before any further intensive systemic therapy [@20250624|14501112].  \n- Document ECOG, comorbidities, nutrition, symptom and pain burden, and stoma function today to set realistic treatment intensity.  \n- Obtain updated contrast-enhanced CT/MRI with formal comparison to 2025-04-09 CT to define metastatic pattern and complications; defer PET/CT.  \n- Retrieve/clarify full ovarian pathology and pursue feasible biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2) or re-biopsy if necessary.  \n- Engage palliative care for symptom control, nutritional support, and anemia/stoma management; reconsider systemic options once clinical and disease status clarified.&quot;,
    &quot;oncologist&quot;: &quot;- Defer additional cytotoxic/intensive systemic therapy until anemia is evaluated/treated and ECOG, comorbidities, and symptom burden are documented; currently unknown.  \n\n- Arrange urgent anemia workup and stabilization (including transfusion consideration) before systemic decisions; Hgb 67 g/L [@20250624|14501112].  \n\n- Obtain updated contrast-enhanced CT/MRI with formal comparison to CT 2025-04-09 to define metastatic burden, complications, and guide palliation; details unknown.  \n\n- Retrieve/confirm original ovarian pathology (histology, grade, FIGO, IHC) and perform extended biomarker testing (BRCA/HRD, MSI/TMB, PD‑L1, HER2); all unknown.  \n\n- Reassess systemic options after clinical stabilization, updated imaging, and pathology/molecular clarification, aligning any further treatment with palliative intent and patient goals.&quot;,
    &quot;radiologist&quot;: &quot;- Arrange updated contrast-enhanced CT or MRI, explicitly compared with 2025-04-09 CT, to define metastatic burden and complications [@IMAGING_STUDIES|2025-04-09].  \n- In the new report, detail organ sites (peritoneum, liver, lung/pleura, bone, nodes), lesion sizes, and measurable targets [unknown].  \n- Systematically document complications: bowel obstruction, bowel wall involvement, ascites, pleural effusion, hydronephrosis, biliary obstruction, pathological fractures, venous thrombosis [unknown].  \n- After reviewing updated CT/MRI, reassess whether PET/CT would add management-changing information in this palliative setting [unknown].  \n- Archive and review all prior imaging to establish radiologic trend (progression vs stability) relative to 2025-04-09 baseline [@IMAGING_TRENDS|2025-04-09].&quot;,
    &quot;pathologist&quot;: &quot;- Underlying histologic subtype, grade, FIGO stage, and IHC profile remain unknown; original ovarian pathology must be retrieved/reviewed.  \n\n- Feasibility of extended biomarkers (BRCA/HRD, MSI/TMB, PD‑L1, HER2) on existing blocks vs need for re-biopsy is unknown.  \n\n- Confirm that current metastases match the original ovarian/Müllerian primary and exclude mixed or non-gynecologic primaries once reports available.  \n\n- Verify adequacy and preservation of archived tissue (blocks/slides) for additional IHC and molecular assays before ordering expanded testing.  \n\n- After data retrieval, issue an integrated pathology summary for MDT, detailing subtype, grade, staging parameters, and full biomarker profile.&quot;,
    &quot;nuclear&quot;: &quot;- No PET/CT studies or reports are available; prior metabolic imaging history remains unknown/needs update.  \n\n- Ovarian cancer with multiple metastases is documented, but current distribution and complications await updated contrast CT/MRI [@IMAGING_CONTEXT|2025-04-09].  \n\n- At this time, PET/CT should be deferred until new CT/MRI is reviewed and a management-changing question is clearly defined.  \n\n- Once CT/MRI clarifies sites and complications, PET/CT may help in problem-solving (e.g., equivocal lesions) if it could alter palliation.  \n\n- Without imaging and pathology updates, PET cannot currently be justified for routine restaging or recurrence assessment in this palliative setting.&quot;
  }
}</pre>
  </details>

  <details class="mt">
    <summary>Selected Clinical Context (JSON)</summary>
    <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20250624|14000385&quot;,
        &quot;date&quot;: &quot;2025-06-24T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;白蛋白 39.5 g/l (ALB)\n谷草同工酶 6.9 U/L (ASTM)\n总蛋白 70.5 g/l (TP)\n球蛋白 31.0 g/l (GELO)\n游离脂肪酸 0.30 mmol/L (NEFA)\n尿酸 362 umol/l (UA)\n天冬氨酸氨基转移酶 18.0 U/L (AST)\n直接胆红素 1.7 umol/l (DBIL)\nγ-谷氨酰基转移酶 35 U/L (GGT)\n尿素 11.22 mmol/l (UREA)\n白球比例 1.27 nan (A/G)\n肌酐 93 umol/l (CRE)\n乳酸脱氢酶 209 U/L (LDH)\n丙氨酸氨基转移酶 8.6 U/l (ALT)\n碱性磷酸酶 143.6 U/L (ALP)\n前白蛋白 172 mg/L (PA)\n间接胆红素 1.9 umol/L (IBIL)\n谷氨酸脱氢酶 3.8 U/L (GLDH)\n总胆红素 3.6 umol/l (TBIL)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20250624|14501112&quot;,
        &quot;date&quot;: &quot;2025-06-24T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;红细胞比积 22.3 % (HCT)\n平均红细胞血红蛋白量 27.8 pg (MCH)\n平均PLT容积 8.4 fl (MPV)\n中性淋巴比值 4.14 nan (NL)\n自动审核标志 ACCEPT nan (VFLAG)\n白细胞计数 7.8 *10^9/L (WBC)\n血红蛋白量 67 g/l (HGB)\n平均红细胞体积 92.5 fl (MCV)\n嗜酸性细胞数 0.09 *10^9/L (EOS#)\n嗜酸性细胞% 1.20 % (EOS)\n淋巴细胞% 18.2 % (LYM)\n单核细胞% 6.2 % (MID)\nPLT分布宽度 7 % (PDW)\n嗜碱性细胞数 0.02 *10^9/L (BASO#)\n嗜碱性细胞% 0.30 % (BASO)\n中性粒细胞% 74.1 % (GRAN)\n淋巴细胞数 1.4 *10^9/L (LYM#)\n中性粒细胞数 5.8 *10^9/L (GRAN#)\n红细胞计数 2.41 *10^12/L (RBC)\n血小板计数 198 *10^9/L (PLT)\nRBC分布宽度-CV 16.1 % (RDWCV)\n单核细胞数 0.5 *10^9/L (MID#)\n平均红细胞血红蛋白浓度 300.0 g/l (MCHC)\n血小板压积 0.17 % (PCT)\nRBC分布宽度-SD 56 nan (RDWSD)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20250625|13601595&quot;,
        &quot;date&quot;: &quot;2025-06-25T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;卵巢恶性肿瘤风险值. 98.26 %(绝经后) (ROMA.)\n糖链抗原125 651.00 U/ml (CA125)\n糖链抗原19-9 23.40 U/ml (CA19-9)\n人附睾蛋白4 1210.00 pmol/L (HE4)\n糖链抗原15-3 156.00 U/ml (CA15-3)\n卵巢恶性肿瘤风险值 99.50 %(绝经前) (ROMA)\n癌胚抗原 1.13 ng/ml (CEA)\n甲胎蛋白 1.04 ng/ml (AFP)&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;20250624|14000385&quot;,
        &quot;date&quot;: &quot;2025-06-24T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;白蛋白 39.5 g/l (ALB)\n谷草同工酶 6.9 U/L (ASTM)\n总蛋白 70.5 g/l (TP)\n球蛋白 31.0 g/l (GELO)\n游离脂肪酸 0.30 mmol/L (NEFA)\n尿酸 362 umol/l (UA)\n天冬氨酸氨基转移酶 18.0 U/L (AST)\n直接胆红素 1.7 umol/l (DBIL)\nγ-谷氨酰基转移酶 35 U/L (GGT)\n尿素 11.22 mmol/l (UREA)\n白球比例 1.27 nan (A/G)\n肌酐 93 umol/l (CRE)\n乳酸脱氢酶 209 U/L (LDH)\n丙氨酸氨基转移酶 8.6 U/l (ALT)\n碱性磷酸酶 143.6 U/L (ALP)\n前白蛋白 172 mg/L (PA)\n间接胆红素 1.9 umol/L (IBIL)\n谷氨酸脱氢酶 3.8 U/L (GLDH)\n总胆红素 3.6 umol/l (TBIL)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20250624|14501112&quot;,
        &quot;date&quot;: &quot;2025-06-24T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;红细胞比积 22.3 % (HCT)\n平均红细胞血红蛋白量 27.8 pg (MCH)\n平均PLT容积 8.4 fl (MPV)\n中性淋巴比值 4.14 nan (NL)\n自动审核标志 ACCEPT nan (VFLAG)\n白细胞计数 7.8 *10^9/L (WBC)\n血红蛋白量 67 g/l (HGB)\n平均红细胞体积 92.5 fl (MCV)\n嗜酸性细胞数 0.09 *10^9/L (EOS#)\n嗜酸性细胞% 1.20 % (EOS)\n淋巴细胞% 18.2 % (LYM)\n单核细胞% 6.2 % (MID)\nPLT分布宽度 7 % (PDW)\n嗜碱性细胞数 0.02 *10^9/L (BASO#)\n嗜碱性细胞% 0.30 % (BASO)\n中性粒细胞% 74.1 % (GRAN)\n淋巴细胞数 1.4 *10^9/L (LYM#)\n中性粒细胞数 5.8 *10^9/L (GRAN#)\n红细胞计数 2.41 *10^12/L (RBC)\n血小板计数 198 *10^9/L (PLT)\nRBC分布宽度-CV 16.1 % (RDWCV)\n单核细胞数 0.5 *10^9/L (MID#)\n平均红细胞血红蛋白浓度 300.0 g/l (MCHC)\n血小板压积 0.17 % (PCT)\nRBC分布宽度-SD 56 nan (RDWSD)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20250625|13601595&quot;,
        &quot;date&quot;: &quot;2025-06-25T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;卵巢恶性肿瘤风险值. 98.26 %(绝经后) (ROMA.)\n糖链抗原125 651.00 U/ml (CA125)\n糖链抗原19-9 23.40 U/ml (CA19-9)\n人附睾蛋白4 1210.00 pmol/L (HE4)\n糖链抗原15-3 156.00 U/ml (CA15-3)\n卵巢恶性肿瘤风险值 99.50 %(绝经前) (ROMA)\n癌胚抗原 1.13 ng/ml (CEA)\n甲胎蛋白 1.04 ng/ml (AFP)&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  }
}</pre>
  </details>

  <details class="mt">
    <summary>Global Guideline RAG</summary>
    <h3>RAG Query</h3>
    <pre>Heavily pretreated recurrent ovarian cancer, platinum status unclear, with multiple metastases on CT; no BRCA/HRD/MSI/PD-L1 data; significant anemia (Hgb 67), hypoalbuminemia, prior bowel obstruction with stoma—guidance on further systemic options and goals of care?</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre>(RAG: no evidence found)</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[]</pre>
    <h3>Digest (<=8 bullets)</h3>
    <pre>- No directly relevant guideline or trial evidence was identified in the provided RAG search; MDT decisions should be based on standard, up-to-date disease-specific guidelines (e.g., NCCN, ESMO, ASCO) and institutional protocols.  
- In the absence of RAG-sourced evidence, MDT should verify current recommendations from major guidelines for staging, risk stratification, and initial management of the specific cancer type involved.  
- Treatment planning should default to guideline-concordant standard-of-care regimens (systemic therapy, surgery, radiotherapy) appropriate to stage, biomarkers, performance status, and comorbidities, as defined in contemporary international guidelines.  
- Where guideline options are equivalent, MDT should weigh toxicity profiles, route/schedule of administration, patient preferences, and local resource availability.  
- If the clinical scenario is uncommon or involves multiple competing options, MDT should consider referral to or discussion with a disease-site specialist center and review of primary literature beyond the RAG system.  
- For situations with true guideline gaps (e.g., rare histologies, unusual biomarker constellations), MDT may consider enrollment in clinical trials or use of extrapolated evidence from analogous tumor types per expert consensus.  
- MDT should document the rationale for chosen management, explicitly noting when decisions are based on expert opinion or extrapolation rather than high-level trial/guideline evidence.  
- Plan for reassessment according to guideline-recommended response and surveillance intervals, with readiness to adjust management in line with emerging evidence or new guideline updates.</pre>
  </details>

  <details class='mt' open><summary>Pipeline Flow (Mermaid)</summary><pre class='mermaid'>flowchart TD
  A[Load Case + Fingerprint] --&gt; B[Load Reports]
  B --&gt; C[Report Selection per Role]
  C --&gt; D[Global Guideline RAG]
  D --&gt; E[Init Specialist Agents]
  E --&gt; F[MDT Discussion Engine]
  F --&gt; G[Trial Matching]
  G --&gt; H[Final Chair Output]
  H --&gt; I[Save Logs]
</pre></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-17T20:42:09.768813&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2025-06-27 15:54:59.567000&quot;,
      &quot;meta_info&quot;: &quot;362201196403235065&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:42:09.769170&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;d9b11a1ab0f2&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:42:10.036644&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 16,
      &quot;img_n&quot;: 2,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 0,
      &quot;cutoff_dt&quot;: &quot;2025-06-28 15:54:59&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:42:16.897871&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [
          &quot;20250624|14000385|2025-06-24&quot;,
          &quot;20250624|14501112|2025-06-24&quot;,
          &quot;20250625|13601595|2025-06-25&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;20250624|14000385|2025-06-24&quot;,
          &quot;20250624|14501112|2025-06-24&quot;,
          &quot;20250625|13601595|2025-06-25&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:42:45.504889&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;Heavily pretreated recurrent ovarian cancer, platinum status unclear, with multiple metastases on CT; no BRCA/HRD/MSI/PD-L1 data; significant anemia (Hgb 67), hypoalbuminemia, prior bowel obstruction with stoma—guidance on further systemic options and goals of care?&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:42:45.504898&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;topk&quot;: 5,
      &quot;n&quot;: 0
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:42:49.730496&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:45:38.714504&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 3934
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:45:38.715138&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:46:05.613837&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 1267
    }
  }
]</pre>
  </details>

</body>
</html>
